Elisabeth Leiderman

2021

In 2021, Elisabeth Leiderman earned a total compensation of $569.9K as Former Chief Financial Officer and Head of Corporate Development at Decibel Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$160,000
Salary$397,308
Other$12,590
Total$569,898

Leiderman received $397.3K in salary, accounting for 70% of the total pay in 2021.

Leiderman also received $160K in non-equity incentive plan and $12.6K in other compensation.

Rankings

In 2021, Elisabeth Leiderman's compensation ranked 10,433rd out of 12,406 executives tracked by ExecPay. In other words, Leiderman earned more than 15.9% of executives.

ClassificationRankingPercentile
All
10,433
out of 12,406
16th
Division
Manufacturing
4,614
out of 5,492
16th
Major group
Chemicals And Allied Products
2,068
out of 2,368
13th
Industry group
Drugs
1,834
out of 2,089
12th
Industry
Pharmaceutical Preparations
1,358
out of 1,536
12th
Source: SEC filing on April 28, 2023.

Leiderman's colleagues

We found three more compensation records of executives who worked with Elisabeth Leiderman at Decibel Therapeutics in 2021.

2021

John Lee

Decibel Therapeutics

Executive Vice President, Chief Development Officer

2021

Laurence Reid

Decibel Therapeutics

Chief Executive Officer

2021

Anna Trask

Decibel Therapeutics

Executive Vice President, Chief People Officer

News

You may also like